Pharmaceutical Research Laboratories in Bank Of New York, New York

Retrophin Inc, New York

New York / New York / United States

0.0

Pharmaceutical Research Laboratories

Detail

Pfizer, New York

New York / New York / United States

0.0

Pfizer, founded in 1849, is one of the largest research-based pharmaceuticals companies in the United States. The company s areas of expertise include human and animal health, and consumer health care products. Its human health segment offers medicines for cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye diseases and allergies. The consumer health care segment produces and markets various medications for oral care, upper respiratory and gastrointestinal health, tobacco dependence, skin and eye care, and hair growth. The company s animal health division develops products for the prevention and treatment of diseases in livestock and companion animals. The products offered by the division include parasiticides, anti-inflammatories, vaccines, and antibiotics. The company s well-known brands include Sudafed, Listerine, Benadryl, Lipitor, Diflucan, Zithromax, Viagra and Celebrex. It also produces pharmaceutical chemicals and gelatin capsules, and offers contract-manufacturing services. Pfizer has various subsidiaries, including Warner-Lambert, Parke-Davis, and Goedecke, and is headquartered in New York City.

Detail

Shire PLC, New York

New York / New York / United States

0.0

Detail

Anavex Life Sciences Corp, New York

New York / New York / United States

0.0

Pharmaceutical Research Laboratories

Detail

AngioGenex, Inc, New York

New York / New York / United States

0.0

Founded in 1999, AngioGenex is a publicly held biopharmaceutical company that is engaged in the development of applications based on research into Id genes and proteins. It specializes in the discovery of Id-based products for the treatment and diagnosis of cancer and therapeutic care applications. The company additionally develops drugs for diabetes, retinopathy and endometriosis. It provides diagnostic products for oncological conditions and breast, melanoma and cervical cancers. The company specializes in a variety of procedures, such as coronary artery bypass grafting, balloon angioplasty and stent placement. AngioGenex has a partnership with BioCheck for the development and research of diagnostic and treatment products.

Detail

Lescarden Inc, New York

New York / New York / United States

0.0

Lescarden is a publicly owned biotechnology company focused on the development of natural biologic therapies for the chronic wound care, dermatology and osteoarthritis markets. The company s flagship product is Catrix, a highly refined powder made from tracheal cartilage. The product is approved by the U.S. Food and Drug Administration for use in the management of a wide range of wounds, including chronic skin ulcers and burns. In addition, Catrix is recognized for its therapeutically diverse systemic and topical applications, including chronic wound healing, dermatology and skin care, inflammatory joint disease and metastatic renal cell cancer treatments. The company also markets the Catrix Skin Care line of topical products used to relieve irritation and expedite healing following dermatologic procedures. Lescarden maintains its laboratory facilities and corporate headquarters in New York.

Detail

Actinium Pharmaceuticals, Inc, New York

New York / New York / United States

0.0

Pharmaceutical Research Laboratories

Detail

Phosplatin Therapeutics, New York

New York / New York / United States

0.0

Detail

EasyVista, Inc, New York

New York / New York / United States

0.0

POZEN is a pharmaceutical company that develops products for the treatment of acute chronic pain and pain-related conditions. The company develops therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety and patient convenience. Since its inception, POZEN has focused its efforts primarily on the development of pharmaceutical products for the treatment of acute and chronic pain, migraine or other pain related conditions. Its lead product candidate is Trexima, which is being developed by the company in collaboration with GlaxoSmithKline for the treatment of acute migraine headaches. POZEN is headquartered in Chapel Hill, N.C.

Detail

Pharmotech Chemogan Pharmaceuticals photos

Pharmotech Chemogan Pharmaceuticals, New York

New York / New York / United States

0.0

Detail

Progenics Pharmaceuticals, Inc, New York

New York / New York / United States

0.0

Progenics Pharmaceuticals is a biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The principal Progenics programs are directed toward symptom management and supportive care, HIV, infection and cancer. The company has five product candidates in clinical development and several others in preclinical development. The Progenics Pharmaceuticals product candidate in the area of symptom management and supportive care is methylnaltrexone, a compound in pivotal phase 3 clinical testing. MNTX is designed to treat the debilitating side effects of narcotic-based pain relievers, which are referred to as opioid analgesics without interfering with pain relief. Progenics Pharmaceuticals maintains a location in Tarrytown, N.Y.

Detail

IVERIC bio, Inc, New York

New York / New York / United States

0.0

Detail

Immunovant, Inc, New York

New York / New York / United States

0.0

Pharmaceutical Research Laboratories

Detail

OHR Pharmaceutical Inc, New York

New York / New York / United States

0.0

Pharmaceutical Research Laboratories

Detail

Sellas Life Sciences Group, Inc, New York

New York / New York / United States

0.0

RXi Pharmaceuticals Corporation is a discovery-stage biopharmaceutical company that is engaged in the development and potential commercialization of proprietary therapeutics. It conducts various research studies based on RNA interference for the treatment of human diseases. The company offers the rxRNA compound, which is potent and nuclease resistant. Its products have potential uses in the recovery of several inflammatory diseases, such as rheumatoid arthritis, Crohn s disease, atherosclerosis and diabetes. RXi Pharmaceuticals Corporation s oligonucleotide-based product research is sponsored by the Drug Information Association. It additionally works in collaboration with the University of Massachusetts for the development of orally delivered RNA interference therapeutic technologies.

Detail